Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;13(2):67-73.
doi: 10.1016/j.prnil.2025.03.003. Epub 2025 Mar 18.

Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data

Arya Bahadori  1 , Jessie Woods  1 , Lance Yuan  1 , Louise Emmett  2   3 , John Yaxley  1   4   5 , Matthew J Roberts  1   4   6
Affiliations
Review

Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data

Arya Bahadori et al. Prostate Int. 2025 Jun.

Abstract

Prostate biopsy prior to radical treatment for prostate cancer is a common practice worldwide to allow diagnosis, prognostication, and treatment planning. However, recent advances in prostate multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) have made the possibility of a "biopsy-free" radical prostatectomy, without prior biopsy, closer to reality than before. The biopsy-free approach serves to avoid investigation-related morbidity, health care resources, and time to definitive treatment, but is not without risk. Here we review the literature surrounding the rationale, limitations, and current data.

Keywords: Biopsy; Multiparametric magnetic resonance imaging; Prostate cancer; Prostate-specific membrane antigen positron emission tomography; Radical prostatectomy.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Potentially suitable patient for biopsy-free radical prostatectomy, with imaging suspicious for high-risk prostate cancer. Panels A-B: mpMRI showing PIRADS 5 lesion with broad capsular abutment, Panels C-D PSMA-PET scan showing highly avid primary tumor (SUVmax 24) suspicious for seminal vesicle invasion.
Fig. 2
Fig. 2
False-positive case demonstrating highly suspicious imaging (mpMRI, PSMA-PET) with no cancer on biopsy. Panels A-C: MRI images showing no suspicious lesion present (PIRADS 2); Panels D-E: PSMA-PET scan showing focal, high PSMA uptake (SUV max 17.3).
See this image and copyright information in PMC

References

    1. James N.D., Tannock I., N'Dow J., Feng F., Gillessen S., Ali S.A., et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683–1722. - PMC - PubMed
    1. Moses K.A., Sprenkle P.C., Bahler C., Box G., Carlsson S.V., Catalona W.J., et al. NCCN Guidelines® insights: prostate cancer early detection, version 1.2023: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2023;21:236–246. - PubMed
    1. Mottet N., van den Bergh R.C.N., Briers E., Van den Broeck T., Cumberbatch M.G., De Santis M., et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–262. - PubMed
    1. Wei J., Barocas D., Carlsson S. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):45–53. - PMC - PubMed
    1. Parker C., Castro E., Fizazi K., Heidenreich A., Ost P., Procopio G., et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1119–1134. - PubMed

LinkOut - more resources